November 15th, 2023 “EURETINA-Brief”© Issue No. 281
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 15th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA…
EURETINA’s
DIGITAL
NEWSLETTER
1
Featured Articles
November 15th, 2023
Latest News
Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has…
Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization.
Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual…
Researchers at University Hospital Zurich have reported a novel dual AAV strategy aimed to correct ABCA4 gene mutations for Stargardt disease (STGD1).
Researchers at the Laboratory for Retinal Gene Therapy, Department of Ophthalmology, University Hospital Zurich, Switzerland,…
November 15th, 2023 “EURETINA-Brief”© Issue No. 281
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 15th,…